智通财经网·2025-10-17 11:19Core Points - Fosun Pharma announced a capital increase agreement with Shenzhen Biomedical Industry Fund for its subsidiary Fosun Kerry, involving a total investment of 600 million yuan for A-round financing [1] - The funds raised will be used for the operation and business development of Fosun Kerry and/or its subsidiaries [1] - A co-investment agreement was signed with 14 participants, including current directors and core management, committing a total of 3.525 million yuan to increase Fosun Kerry's registered capital [1] - The pre-investment valuation for this co-investment aligns with the capital increase [1] Related Transactions - The co-investors include several directors and senior management, which constitutes a related party transaction under the Shanghai Stock Exchange Listing Rules [2] - These related party co-investors plan to contribute a total of 1.246664 million yuan to increase Fosun Kerry's registered capital [2] Incentive Plan - To attract and retain key talent, Fosun Kerry's board approved an incentive plan on October 17, 2025, allowing for the issuance of equity incentives valued at up to 93.219893 million yuan [3] - The first batch of incentives will grant up to 76.184870 million yuan in registered capital [3] - The equity incentives will be sourced from shares transferred to the incentive platform by Fosun Pharma's subsidiary [3] Related Party Incentives - The first batch of incentive recipients includes several directors and senior management, which also constitutes a related party transaction [4] - If all granted incentives are fully vested, these related party recipients could indirectly hold 12.755472 million yuan in registered capital through an investment of 9.694159 million yuan [4]